Homology Medicines, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 32.95 million compared to USD 33.73 million a year ago. Basic loss per share from continuing operations was USD 10.26 compared to USD 10.62 a year ago. Diluted loss per share from continuing operations was USD 10.26 compared to USD 10.62 a year ago.
For the nine months, net loss was USD 96.84 million compared to net income of USD 29.29 million a year ago. Basic loss per share from continuing operations was USD 30.24 compared to basic earnings per share from continuing operations of USD 9.18 a year ago. Diluted loss per share from continuing operations was USD 30.24 compared to diluted earnings per share from continuing operations of USD 9.18 a year ago.